InCarda Therapeutics Issued Broad Patents in U.S., Australia and Canada
Palo Alto, California, October 6, 2015 – InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company focused on the development and commercialization of therapies for acute cardiovascular conditions via the inhalation route, today announced the issuance of patents in the United States, Australia and Canada, which cover the company’s lead product candidate. The United States patent, No. 8,974,828, issued in March 2015 and is entitled “Unit doses, aerosols, kits and methods for treating heart conditions by pulmonary administration.” InCarda’s lead product in development consists of an established drug for paroxysmal atrial fibrillation (PAF) delivered in a novel way, via inhalation.
“The issuance of this important patent strengthens the IP position around our product candidates, protecting our novel and exciting product platform. We continue to add to our patent estate with additional proprietary concepts we believe will transform cardiovascular care,” stated Grace E. Colón, Ph.D., chief executive officer and president of InCarda. “It appears that delivery of effective cardiovascular medications through the pulmonary system may provide much quicker relief of symptoms and significantly reduce the burden on the healthcare system related to these cardiovascular episodes.”
“Flecainide is a first line drug of choice to treat Paroxysmal Atrial Fibrillation (PAF) in patients with minimal structural heart disease. At InCarda we are developing a fast acting inhaled version of this drug for quick relief from the disabling symptoms often experienced with an acute episode,” stated Narsi Rangachari, M. Pharm., chief operating officer, co-founder, and inventor on the patent. “Our products, given their pulmonary route of administration, have the unique potential to treat patients in the first moments following a cardiovascular event, and this could revolutionize the way these common events are treated,” added Carlos Schuler, Ph.D., chief scientific officer, co-founder and inventor on the patent.
InCarda’s Lead Product for PAF
Paroxysmal Atrial Fibrillation, the most common type of cardiac arrhythmia (abnormal heart rhythm) is an episode patients experience when the heart flutters instead of beating normally. Flecainide is commonly prescribed for arrhythmias, and InCarda is evaluating an inhaled formulation of the drug for patients experiencing PAF. Preparations are being made and a toxicology study is underway to optimize the product in advance of commencing a Phase 1 clinical trial in early 2016.
About InCarda (www.incardatherapeutics.com)
InCarda Therapeutics, located in the San Francisco Bay Area with operations in Australia, is focused on transforming cardiovascular disease treatment through pulmonary delivery of established drugs. The company is product-focused with significant capabilities and led by a team with extensive experience in drug development. The lead product under development is an inhaled therapy intended to treat paroxysmal atrial fibrillation (PAF). InCarda is also working on additional research concepts that leverage the same platform technology to target the heart for acute cardiac conditions. Our approach is designed to reduce the risk normally associated with drug development. Our model is based on the following three tenets: known diseases, known drugs, new delivery.
Contact Information:
Tim Brons
Vida Strategic Partners (media)
646-319-8981
tbrons@vidasp.com